Negative in Ames, in vitro human lymphocyte micronucleus and in vivo rat bone marrow micronucleus assays
“Brexanolone was not genotoxic when tested in an in vitro microbial mutagenicity (Ames) assay, an in vitro micronucleus assay in human peripheral blood lymphocytes, and an in vivo rat bone marrow micronucleus assay.”
“Brexanolone was not assessed for carcinogenicity because the treatment of PPD with brexanolone infusion is considered acute.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat and rabbit EFD: no malformations up to 5-6x MRHD; developmental toxicity at 5x (rat) and >=3x (rabbit)
“In animal reproduction studies, malformations were not seen in rats or rabbits at plasma levels up to 5 and 6 times the maximum recommended human dose (MRHD), respectively. Developmental toxicities were seen in the fetuses of rats and rabbits at 5 and ≥3 times the plasma levels at the MRHD, respectively.”
CNS (rat FOB) and cardiovascular/respiratory (dog) endpoints embedded in 14-day toxicology studies
“CNS safety pharmacology was evaluated as part of the 14-day rat toxicology study using a Functional Observation Battery (FOB). Cardiovascular and respiratory safety pharmacology was evaluated as part of the 14-day dog toxicology study”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Genotox: Ames
Negative (Ames)
“SAGE-547 was negative for mutagenicity in bacterial cells in a valid Ames test.”
✓ VerifiedFDA multi-discipline review, p. 53Source ↗
Genotox: in vitro mammalian
In vitro human lymphocyte micronucleus: negative
“SAGE-547 was negative for clastogenicity in human lymphocytes in a valid in vitro micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 53Source ↗
Genotox: in vivo
Rat bone marrow micronucleus: negative at 34x clinical exposure
“SAGE-547 was not clastogenic in a valid in vivo micronucleus assay at plasma concentrations 34-times clinical exposure.”
✓ VerifiedFDA multi-discipline review, p. 54Source ↗
Carcinogenicity model
Not conducted (short-term treatment, 2.5 days)
“Because brexanolone use for PPD is considered a short-term treatment (2.5 days), carcinogenicity studies were not conducted.”
✓ VerifiedFDA multi-discipline review, p. 54Source ↗
Carcinogenicity timing
Not required; acute treatment of postpartum depression
“Brexanolone was not assessed for carcinogenicity because the treatment of PPD with brexanolone infusion is considered acute.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
hERG / QT
hERG IC50 >6.6 µM (solubility-limited), >28x clinical exposure at MRHD
“IC50 > 6.6 µM (SAGE-547 insoluble in assay vehicle at higher concentrations), which is greater than 28-times the clinical exposures at the MRHD.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative